{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:47:14Z","timestamp":1782107234138,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01514-x","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:56:15Z","timestamp":1782104175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Positioning Zolbetuximab in HER2-Negative Advanced Gastric Cancer: A Practical Framework for Treatment Selection in the ICI Era"],"prefix":"10.1007","volume":"57","author":[{"given":"Tamotsu","family":"Sagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"issue":"2","key":"1514_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10120-025-01698-4","volume":"29","author":"Japanese Gastric Cancer Association","year":"2026","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2025 (7th edition). Gastric Cancer. 2026;29(2):271\u201399. https:\/\/doi.org\/10.1007\/s10120-025-01698-4.","journal-title":"Gastric Cancer"},{"key":"1514_CR2","unstructured":"Japanese Gastric Cancer Association. Guide for biomarker testing in unresectable advanced\/recurrent gastric cancer. 2nd ed [Internet]. Tokyo: Japanese Gastric Cancer Association. 2025 May 20 [cited 2026 Mar 29]. Available from: https:\/\/www.jgca.jp\/wp-content\/uploads\/2025\/05\/tebiki_02_202505.pdf. [in Japanese]."},{"issue":"10389","key":"1514_CR3","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7.","journal-title":"Lancet"},{"issue":"8","key":"1514_CR4","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02465-7.","journal-title":"Nat Med"},{"key":"1514_CR5","unstructured":"Astellas Pharma US. Inc. VYLOY (zolbetuximab-clzb) for injection, for intravenous use: prescribing information [Internet]. Northbrook (IL): Astellas Pharma US, Inc.; 2025 [cited 2026 Mar 29]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761365s003lbl.pdf"},{"key":"1514_CR6","unstructured":"U.S. Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED): VENTANA CLDN18 (43-14A) RxDx Assay. PMA P230018 [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2024 [cited 2026 Mar 29]. Available from: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf23\/P230018B.pdf"},{"issue":"10111","key":"1514_CR7","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(17)31827-5.","journal-title":"Lancet"},{"key":"1514_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2026.2642222","author":"H Kawakami","year":"2026","unstructured":"Kawakami H, Tanizawa Y, Shimizu T. Real-world sequential treatment patterns and outcomes in the new era of immunotherapy for advanced gastric cancer in Japan. Future Oncol. 2026. https:\/\/doi.org\/10.1080\/14796694.2026.2642222.","journal-title":"Future Oncol"},{"issue":"23","key":"1514_CR9","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14(23):7624\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1547.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1514_CR10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","volume":"32","author":"U Sahin","year":"2021","unstructured":"Sahin U, T\u00fcreci \u00d6, Manikhas G, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32(5):609\u201319. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.005.","journal-title":"Ann Oncol"},{"issue":"11","key":"1514_CR11","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(23)00515-6.","journal-title":"Lancet Oncol"},{"issue":"10294","key":"1514_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"issue":"4 suppl","key":"1514_CR13","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/JCO.2025.43.4_suppl.398","volume":"43","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, et al. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric\/gastroesophageal junction (G\/GEJ)\/esophageal adenocarcinoma (EAC): 5-year update from CheckMate 649. J Clin Oncol. 2025;43(4 suppl):398. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.398.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1514_CR14","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.004.","journal-title":"Ann Oncol"},{"key":"1514_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04306-9","author":"K Shitara","year":"2026","unstructured":"Shitara K, Shoji H, Fazio N, et al. First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. Nat Med. 2026. https:\/\/doi.org\/10.1038\/s41591-026-04306-9.","journal-title":"Nat Med"},{"issue":"2 suppl","key":"1514_CR16","doi-asserted-by":"publisher","first-page":"TPS473","DOI":"10.1200\/JCO.2026.44.2_suppl.TPS473","volume":"44","author":"K Shitara","year":"2026","unstructured":"Shitara K, Enzinger PC, Lordick F, et al. Zolbetuximab plus pembrolizumab and chemotherapy as first-line treatment for patients with CLDN18.2-positive, HER2-negative, PD-L1-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: phase 3, double-blind, randomized trial (LUCERNA). J Clin Oncol. 2026;44(2 suppl):TPS473. https:\/\/doi.org\/10.1200\/JCO.2026.44.2_suppl.TPS473.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1514_CR17","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","volume":"19","author":"K Shitara","year":"2018","unstructured":"Shitara K, Doi T, Dvorkin M, et al. Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric or gastric oesophageal junction cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(11):1437\u201348. https:\/\/doi.org\/10.1016\/S1470-2045(18)30739-3.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1514_CR18","doi-asserted-by":"publisher","first-page":"100589","DOI":"10.1016\/j.modpat.2024.100589","volume":"37","author":"M Fassan","year":"2024","unstructured":"Fassan M, Kuwata T, Matkowskyj KA, et al. Claudin-18.2 immunohistochemical evaluation in gastric and gastroesophageal junction adenocarcinomas to direct targeted therapy: a practical approach. Mod Pathol. 2024;37(11):100589. https:\/\/doi.org\/10.1016\/j.modpat.2024.100589.","journal-title":"Mod Pathol"},{"issue":"1","key":"1514_CR19","doi-asserted-by":"publisher","first-page":"17648","DOI":"10.1038\/s41598-024-68411-w","volume":"14","author":"E Choi","year":"2024","unstructured":"Choi E, Shin J, Ryu MH, Kim HD, Park YS. Heterogeneity of claudin 18.2 expression in metastatic gastric cancer. Sci Rep. 2024;14(1):17648. https:\/\/doi.org\/10.1038\/s41598-024-68411-w.","journal-title":"Sci Rep"},{"key":"1514_CR20","unstructured":"Japan Society of Clinical Oncology. Anti-emetic therapy during first-line chemotherapy containing zolbetuximab for HER2-negative, Claudin 18.2-positive unresectable advanced\/recurrent gastric cancer: flash report of the clinical practice guidelines for antiemesis [Internet]. Tokyo: Japan Society of Clinical Oncology; 2025 [cited 2026 Mar 29]. Available from: https:\/\/www.jsco.or.jp\/Portals\/0\/5_Guideline\/Flash%20report%20of%20the%20CPG%20for%20antiemesis_2025Feb%20%28002%29.pdf"},{"issue":"9","key":"1514_CR21","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1038\/s41591-025-03783-8","volume":"31","author":"J Liu","year":"2025","unstructured":"Liu J, Yang J, Sun Y, et al. CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial. Nat Med. 2025;31(9):3028\u201336. https:\/\/doi.org\/10.1038\/s41591-025-03783-8.","journal-title":"Nat Med"},{"issue":"23","key":"1514_CR22","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1158\/1078-0432.CCR-24-4280","volume":"31","author":"G Ku","year":"2025","unstructured":"Ku G, Shen L, Dayyani F, et al. A first-in-human study of givastomig, a CLDN18.2 and 4-1BB bispecific antibody, as monotherapy in patients with CLDN18.2-positive advanced or metastatic solid tumors. Clin Cancer Res. 2025;31(23):4944\u201352. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-4280.","journal-title":"Clin Cancer Res"},{"issue":"10494","key":"1514_CR23","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","volume":"405","author":"C Qi","year":"2025","unstructured":"Qi C, Liu C, Peng Z, et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet. 2025;405(10494):2049\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(25)00860-8.","journal-title":"Lancet"},{"issue":"9","key":"1514_CR24","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1200\/JCO.20.00892","volume":"39","author":"MH Moehler","year":"2021","unstructured":"Moehler MH, Dvorkin M, Boku N, et al. Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN Gastric 100. J Clin Oncol. 2021;39(9):966\u201377. https:\/\/doi.org\/10.1200\/JCO.20.00892.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01514-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01514-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01514-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:56:19Z","timestamp":1782104179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01514-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1514"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01514-x","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"139"}}